YC Hwang, RM Lu, SC Su, PY Chiang, SH Ko… - Journal of Biomedical …, 2022 - Springer
… specificity and reliability, monoclonalantibodies (mAbs) … coronavirus 2 (SARS-CoV-2) and Ab drugs for use as COVID-19 therapeutic agents. The detailed structure of the SARS-CoV-2 …
E Quiros-Roldan, S Amadasi, I Zanella, M Degli Antoni… - Pharmaceuticals, 2021 - mdpi.com
… Numerous mAbs have been developed against SARS-CoV 2 and have proven their … describe the monoclonalantibodies currently authorized for the treatment of the coronavirus disease …
… Monoclonalantibodies (mAbs) targeting the spike protein of SARS-CoV-2 have been widely used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs …
D Yamasoba, Y Kosugi, I Kimura, S Fujita… - The Lancet Infectious …, 2022 - thelancet.com
… of newly emerging SARS-CoV-2 variants, we suggest the importance of rapid evaluation of the efficiency of therapeutic monoclonalantibodies against novel SARS-CoV-2 variants. …
JD Berry, S Jones, MA Drebot, A Andonov… - Journal of virological …, 2004 - Elsevier
… Monoclonalantibody reagents that recognise specific antigens on SARS-CoV are needed … a panel of murine monoclonalantibodies (mAbs) against the SARS-CoV is presented, based …
… neutralizing antibodies against variant strains of SARS-CoV-2 … activity of a panel of monoclonal antibodies (mAbs), which … , Regeneron and Lilly, against SARS-CoV-2 variant viruses. …
C Wang, W Li, D Drabek, NMA Okba… - Nature …, 2020 - nature.com
… report a human monoclonalantibody that neutralizes SARS-CoV-2 (and SARS-CoV) in cell … first report of a (human) monoclonalantibody that neutralizes SARS-CoV-2. 47D11 binds a …
… Monoclonalantibodies (mAbs) offer a treatment option for … evolution of resistance to mAbs by SARS-CoV-2, we reviewed … is being reported with new SARS-CoV-2 variants. The …
… Monoclonalantibody (mAb) therapy has been previously exploited for viral … SARS-CoV-2 mAbs. While many candidates are in preclinical development, we focus here on anti-SARS-CoV…